Your session is about to expire
← Back to Search
Pelabresib for Cancer
Study Summary
This trial will look at the effects of food on how the body processes a new cancer drug, and also how the drug affects heart function.
- Advanced Cancers
- Solid Tumors
- Blood Cancers
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a medical condition or are taking medication that would make it impossible for you to receive treatment.You have a type of cancer that has spread and no standard treatments are available to help.
- Group 1: Continuous Treatment Period
- Group 2: Run-In Food Effect Period
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA given their stamp of approval to Pelabresib?
"Our team at Power gave Pelabresib a score of 1 due to the limited amount of clinical data available on its safety and efficacy. This is because this trial is currently in phase 1."
What is the current enrollment count for this clinical research endeavor?
"According to the specified inclusion criteria, 32 patients must be enrolled in this trial. Potential participants can sign up at Gabrail Cancer Center Research (Canton, Ohio) and Start Mountain Region (West Valley City, Utah)."
Are there still opportunities to enroll in this research program?
"Affirmative. The latest data from clinicaltrials.gov reveals that this research study, which was initially advertised on July 26th 2021 is actively recruiting participants and is looking for 32 people across 3 centres."
Share this study with friends
Copy Link
Messenger